Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated With Endometriosis During Treatment and Post Treatment in Reproductive-Aged Women
1 other identifier
interventional
150
7 countries
70
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive aged women.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started May 2006
Shorter than P25 for phase_2
70 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 24, 2006
CompletedFirst Posted
Study publicly available on registry
April 26, 2006
CompletedStudy Start
First participant enrolled
May 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2006
CompletedDecember 10, 2007
December 1, 2007
April 24, 2006
December 7, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
severity scores for dysmenorrhea, pelvic pain and deep dyspareunia from baseline through 12 weeks of treatment using the B & B scale administered by the investigator
Secondary Outcomes (3)
change in severity scores for pelvic tenderness and pelvic induration during 12 weeks of treatment
change in rescue medication use
change in health related quality of life questionnaires
Interventions
Eligibility Criteria
You may qualify if:
- Surgical diagnosis of endometriosis within the last 10 years
- Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual cycles who are willing to use non-hormonal contraception
You may not qualify if:
- Conditions requiring the use of chronic pain therapy
- Prophylactic use of analgesics to avoid endometriosis-related pain
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (70)
Unknown Facility
Montgomery, Alabama, 36116, United States
Unknown Facility
Chandler, Arizona, 85225, United States
Unknown Facility
Phoenix, Arizona, 85032, United States
Unknown Facility
Phoenix, Arizona, 85035, United States
Unknown Facility
Tucson, Arizona, 85712, United States
Unknown Facility
San Francisco, California, 94115, United States
Unknown Facility
Vista, California, 92083, United States
Unknown Facility
Denver, Colorado, 80202, United States
Unknown Facility
Denver, Colorado, 80206, United States
Unknown Facility
New Britain, Connecticut, 06050, United States
Unknown Facility
Clearwater, Florida, 33759, United States
Unknown Facility
New Port Richey, Florida, 34652, United States
Unknown Facility
Plantation, Florida, 33324, United States
Unknown Facility
Venice, Florida, 34285, United States
Unknown Facility
West Palm Beach, Florida, 33401, United States
Unknown Facility
West Palm Beach, Florida, 33409, United States
Unknown Facility
Marietta, Georgia, 30066, United States
Unknown Facility
Idaho Falls, Idaho, 83404, United States
Unknown Facility
Oak Brook, Illinois, 60523, United States
Unknown Facility
Evansville, Indiana, 47714, United States
Unknown Facility
Reno, Nevada, 89502, United States
Unknown Facility
Lawrenceville, New Jersey, 08648, United States
Unknown Facility
Durham, North Carolina, 27710, United States
Unknown Facility
New Bern, North Carolina, 28562, United States
Unknown Facility
Raleigh, North Carolina, 27612, United States
Unknown Facility
Winston-Salem, North Carolina, 27103, United States
Unknown Facility
Cleveland, Ohio, 44122, United States
Unknown Facility
Miamisburg, Ohio, 45342, United States
Unknown Facility
Oklahoma City, Oklahoma, 73112, United States
Unknown Facility
Portland, Oregon, 97210, United States
Unknown Facility
Abington, Pennsylvania, 19001, United States
Unknown Facility
Lansdale, Pennsylvania, 19446, United States
Unknown Facility
Philadelphia, Pennsylvania, 19107, United States
Unknown Facility
Philadelphia, Pennsylvania, 19114, United States
Unknown Facility
Pittsburgh, Pennsylvania, 15243, United States
Unknown Facility
Columbia, South Carolina, 29201, United States
Unknown Facility
Greenville, South Carolina, 29607, United States
Unknown Facility
Bristol, Tennessee, 37620, United States
Unknown Facility
Chattanooga, Tennessee, 37403, United States
Unknown Facility
Memphis, Tennessee, 38119, United States
Unknown Facility
Corpus Christi, Texas, 78414, United States
Unknown Facility
San Antonio, Texas, 78229, United States
Unknown Facility
West Valley City, Utah, 84120, United States
Unknown Facility
Norfolk, Virginia, 23507, United States
Unknown Facility
Richmond, Virginia, 23233, United States
Unknown Facility
Richmond, Virginia, 23294, United States
Unknown Facility
Virginia Beach, Virginia, 23456, United States
Unknown Facility
Renton, Washington, 98055, United States
Unknown Facility
Madison, Wisconsin, 53792, United States
Unknown Facility
Randwick, New South Wales, 2031, Australia
Unknown Facility
Sydney, New South Wales, 200, Australia
Unknown Facility
Richmond, Victoria, 3121, Australia
Unknown Facility
Nedlands, Western Australia, 6009, Australia
Unknown Facility
Herestraat, Leuven, 3000, Belgium
Unknown Facility
Calgary, Alberta, T2N 4L7, Canada
Unknown Facility
Vancouver, British Columbia, V6Z 1Y6, Canada
Unknown Facility
Winnipeg, Manitoba, R3A 1R9, Canada
Unknown Facility
Halifax, Nova Scotia, B3H 2N1, Canada
Unknown Facility
London, Ontario, N6A 4V2, Canada
Unknown Facility
Toronto, Ontario, M5B 1W8, Canada
Unknown Facility
Saskatoon, Saskatchewan, S7K 1N4, Canada
Unknown Facility
Hong Kong, Hong Kong
Unknown Facility
Cape Town, Capetown, 7925, South Africa
Unknown Facility
Port Elizabeth, Eastern Cape, 6001, South Africa
Unknown Facility
Roodepoort, Jgb Gauteng, 1724, South Africa
Unknown Facility
Durban, KwaZulu-Natal, 4320, South Africa
Unknown Facility
Nottingham, Nottinghamshire, NG7 2UH, United Kingdom
Unknown Facility
Glasgow, Scotland, G51 4TF, United Kingdom
Unknown Facility
Sheffield, South Yorshire, S10 2SF, United Kingdom
Unknown Facility
Swindon, Wiltshire, SN3 6BD, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Wyeth is now a wholly owned subsidiary of Pfizer
- PRINCIPAL INVESTIGATOR
Trial Manager
For United Kingdom, ukmedinfo@wyeth.com
- PRINCIPAL INVESTIGATOR
Trial Manager
For Australia and Hong Kong, medinfo@wyeth.com
- PRINCIPAL INVESTIGATOR
Trial Manager
For South Africa, ZAFinfo@wyeth.com
- PRINCIPAL INVESTIGATOR
Trial Manager
For Belgium, trials-BEL@wyeth.com
- PRINCIPAL INVESTIGATOR
Trial Manager
For Canada, clintrialparticipation@wyeth.com
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 24, 2006
First Posted
April 26, 2006
Study Start
May 1, 2006
Study Completion
December 1, 2006
Last Updated
December 10, 2007
Record last verified: 2007-12